Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. ConvaTec Group Plc
  6. News
  7. Summary
    CTEC   GB00BD3VFW73

CONVATEC GROUP PLC

(CTEC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ConvaTec : Announces Offering of $500 Million Senior Notes due 2029 30 September 2021

09/30/2021 | 08:42am EST

30 September 2021

London, England-September 30, 2021 - ConvaTec Group Plc (the "Company") announces that it has launched an offering of $500 million aggregate principal amount of senior notes due 2029 (the "Notes") intended to be issued by 180 Medical, Inc. (the "Issuer"). The Notes are being offered only to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") and to certain persons outside the United States in reliance on Regulation S under the Securities Act ("Regulation S"). The interest rate, offering price and certain other terms will be determined at the time of pricing of the Notes, subject to market conditions.

The Company intends to use the proceeds from the offering of the Notes to prepay a portion of borrowings under the facilities agreement dated 24 October 2019 (as amended and/or restated from time to time) between, among others, ConvaTec Finance Holdings Limited and ConvaTec Inc. as original borrowers and National Westminster Bank plc as facility agent and security agent (the "Credit Facility Agreement"). As part of the Transaction, the existing security granted over the shares securing the Credit Facility Agreement will be released.

For more information, please contact:

ConvaTec Group Plc
3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, United Kingdom

ConvaTec Investor Relations:
Phone: +44 (0)118 952 8123
Email: ir@convatec.com

ConvaTec Media Relations:
Phone: +44 (0)118 952 8170
Email: mediarelations@convatec.com


* * *


The offering is being made by means of an offering memorandum. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.


The Notes and the related guarantees have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons (as defined in Regulation S), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Accordingly, the Notes and the related guarantees are being offered and sold (i) in the United States only to qualified institutional buyers in accordance with Rule 144A under the Securities Act and (ii) in "offshore transactions" to non-U.S. persons outside the United States in accordance with Regulation S. There is no assurance that the offerings will be completed or, if completed, as to the terms on which they will be completed.


This announcement has been prepared on the basis that any offer of the Notes in any Member State of the European Economic Area (the "EEA") or in the United Kingdom will be made pursuant to an exemption under Regulation (EU) 2017/1129 (as amended or superseded) (the "Prospectus Regulation") and the Prospectus Regulation as it forms part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018 (the "UK Prospectus Regulation") from the requirement to publish a prospectus for offers of the Notes.


The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA or the United Kingdom. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU, as amended ("MiFID II"); (ii) a customer within the meaning of Directive (EU) 2016/97, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in the Prospectus Regulation and UK Prospectus Regulation. Consequently, no key information document required by Regulation (EU) No 1286/2014, as amended (the "PRIIPs Regulation"), for offering or selling the Notes or otherwise making them available to retail investors in the EEA or in the United Kingdom has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA or the United Kingdom may be unlawful under the PRIIPs Regulation.


Manufacturer target market (MiFID II product governance; UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as the offering is not available to retail investors in EEA or the United Kingdom, respectively.


The distribution of this announcement into certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

Forward-looking Statements

This announcement may include "forward-looking statements" within the meaning of the securities laws of certain applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this announcement, including, without limitation, those regarding the Company's intentions, beliefs or current expectations concerning, among other things: the Company's future financial conditions and performance, results of operations and liquidity; the Company's strategy, plans, objectives, prospects, growth, goals and targets; future developments in the markets in which the Company participates or is seeking to participate; and anticipated regulatory changes in the industry in which the Company operates. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "anticipate", "believe", "continue", "ongoing", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "target", "seek" or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Past performance is not an indication of future results and past performance should not be taken as a representation that trends or activities underlying past performance will continue in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and that the Company's actual financial condition, results of operations and cash flows, and the development of the industry in which the Company operates, may differ materially from (and be more negative). The forward-looking statements in this document speak only as at the date of this announcement and the Company and its affiliates expressly disclaim any obligation or undertaking to review or release any updates or revisions to these forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based after the date of this announcement or to update or to keep current any other information contained in this document or to provide any additional information in relation to such forward-looking statements, unless required to do so by applicable law.

Disclaimer

ConvaTec Group plc published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 12:41:00 UTC.


ę Publicnow 2021
All news about CONVATEC GROUP PLC
01/24Schweitzer-Mauduit International Enters Multi-Year Supply Agreement With ConvaTec
MT
01/12Further progress with ChloraSolv roll out across Europe - market access activities in t..
AQ
01/12RLS Global and ConvaTec Continues Progress with the Distribution and Commercialisation ..
CI
2021ConvaTec Group PLC appoints Kimberly Lody as a non-executive director, effective 1 Febr..
CI
2021FTSE 100 Closes Lower Thursday as Coronavirus-Variant Cases Rise
DJ
2021ConvaTec Names Successor to Outgoing CFO
MT
2021ConvaTec Group Plc Announces Executive Changes
CI
2021ConvaTec Group Plc Announces Board Changes
CI
2021CONVATEC : 25 years of AQUACEL 22 November 2021
PU
2021RLS Global AB secures financing of SEK 20 million
AQ
More news
Analyst Recommendations on CONVATEC GROUP PLC
More recommendations
Financials (USD)
Sales 2021 2 027 M - -
Net income 2021 128 M - -
Net Debt 2021 902 M - -
P/E ratio 2021 38,4x
Yield 2021 2,35%
Capitalization 4 573 M 4 589 M -
EV / Sales 2021 2,70x
EV / Sales 2022 2,53x
Nbr of Employees 9 914
Free-Float 79,9%
Chart CONVATEC GROUP PLC
Duration : Period :
ConvaTec Group Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CONVATEC GROUP PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 2,27 $
Average target price 3,35 $
Spread / Average Target 47,6%
EPS Revisions
Managers and Directors
Karim Sani Nasib Bitar Chief Executive Officer & Director
Frank M. Schulkes Chief Financial Officer & Director
John David Gibson McAdam Chairman
Robert Steele EVP-Quality, Clinical & Regulatory Affairs
Donal Balfe Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
CONVATEC GROUP PLC-12.63%4 586
ABBOTT LABORATORIES-14.69%211 404
MEDTRONIC PLC0.70%140 063
BECTON, DICKINSON AND COMPANY2.63%73 570
HOYA CORPORATION-16.77%46 115
BAXTER INTERNATIONAL INC.-1.83%42 594